ArticleTheranostics2022
Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy.Molecular pharmaceutics · 2026Article
- [International journal of molecular sciences · 2026Article
- FcRn-Targeted Alpha Therapy Using [Molecular imaging and biology · 2026Article
- Diagnostic Twins: Exploring the Radiohybrid Concept with Iodine-123 and Lanthanum-133 for PSMA-Targeted SPECT and PET Imaging.Journal of medicinal chemistry · 2026Article
- Stabilities of AcInorganic chemistry · 2026Article
- Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace.International journal of radiation oncology, biology, physics · 2025Article
- Contemporary review of prognostic markers of prostate cancer from a pathologist perspective.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025Review
- Development of [European journal of nuclear medicine and molecular imaging · 2025Article
- It's a match: use of the radionuclide theranostic pairEJNMMI radiopharmacy and chemistry · 2025Article
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.EJNMMI radiopharmacy and chemistry · 2024Article
- Exploring peptide dendrimers for intestinal lymphatic targeting: formulation and evaluation of peptide dendrimer conjugated liposomes for enhancing the oral bioavailability of Asenapine maleate.Scientific reports · 2024Article
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- Effect of Linker Entities on Pharmacokinetics ofACS pharmacology & translational science · 2024Article
- Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development of CD46 targeted alpha theranostics in prostate cancer usingTheranostics · 2024Article
- Actinium-225 targeted alpha particle therapy for prostate cancer.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Falco ReissigHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Kristof ZarschlerHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Zbynek NovyPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Hnevotinska 1333/5, 779 00 Olomouc, Czech Republic.
Milos PetrikPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Hnevotinska 1333/5, 779 00 Olomouc, Czech Republic.
Katerina BendovaPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Hnevotinska 1333/5, 779 00 Olomouc, Czech Republic.
Daniela KurfurstovaPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Clinical and Molecular Pathology, Hnevotinska 976/3, 775 15 Olomouc, Czech Republic.
Jan BouchalPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Clinical and Molecular Pathology, Hnevotinska 976/3, 775 15 Olomouc, Czech Republic.
Marie-Charlotte LudikHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Florian BrandtHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Marta KhoylouPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Hnevotinska 1333/5, 779 00 Olomouc, Czech Republic.
Hans-Jürgen PietzschHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
Marian HajduchPalacky University Olomouc, Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Hnevotinska 1333/5, 779 00 Olomouc, Czech Republic.
Constantin MamatHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, D‑01328 Dresden, Germany.
TU Dresden · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
RadiopharmaceuticalsSerum AlbuminActiniumAnimalsCell Line, TumorHumansLigandsMaleMiceMice, SCIDTissue DistributionActiniumActinium-225LigandsRadiopharmaceuticalsSerum AlbuminActiniumAlbumin BinderMacropaPSMATargeted Alpha Therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.